Document Detail


A double-blind comparison of intranasal budesonide with placebo for nasal polyposis.
MedLine Citation:
PMID:  2262649     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intranasal budesonide, 400 micrograms two times a day, was evaluated in 36 patients referred for treatment of nasal polyposis. The age range was 20 to 68 years. Polypectomy was done 5.6 (mean) times previously. After a 5-week, treatment-free, baseline period, patients were treated in a double-blind fashion with either budesonide or placebo during 4 weeks. After this treatment period, placebo-treated patients started receiving budesonide in an open trial for an additional 4 weeks. The patients rated their nasal symptoms daily. Nasal examinations and nasal inspiratory flow rate (IFR) measurements were done at clinic visits. After 3 and 4 weeks of treatment, the response to budesonide was significantly greater than response to placebo. The greater reduction in nasal blockage caused by polyps, observed on physical examination, p = 0.005, was mirrored by an increase in nasal IFR (p = 0.0001). Patient rating of the severity and frequency of nasal blockage were reduced more by budesonide than by placebo (p less than or equal to 0.0005). Switching placebo-treated patients to budesonide treatment resulted in a reduction of nasal blockage (p less than 0.001) and an increase in nasal IFR (p less than 0.001). The results demonstrate that topical nasal budesonide, 400 micrograms two times a day, is an effective treatment of nasal polyps.
Authors:
J Ruhno; B Andersson; J Denburg; M Anderson; D Hitch; P Lapp; M Vanzieleghem; J Dolovich
Related Documents :
21167559 - Single incision mid-urethral sling for treatment of female stress urinary incontinence.
21085929 - Clinical and radiographic outcomes of minimally invasive total knee arthroplasty throug...
21438659 - Outcomes of 33 patients from the wars in iraq and afghanistan undergoing bilateral or b...
21555949 - Complication during postacute rehabilitation: patients with posttraumatic hydrocephalus.
21074809 - New ureteral stent design does not improve patient quality of life: a randomized, contr...
21472529 - Total knee arthroplasty in stiff knee compared with flexible knees.
18402739 - Seroma and recurrence in laparoscopic ventral hernioplasty.
15968599 - The prognostic value of dopamine receptor occupancy by [123i]ibzm-spect in schizophreni...
16533249 - Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of allergy and clinical immunology     Volume:  86     ISSN:  0091-6749     ISO Abbreviation:  J. Allergy Clin. Immunol.     Publication Date:  1990 Dec 
Date Detail:
Created Date:  1991-02-01     Completed Date:  1991-02-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1275002     Medline TA:  J Allergy Clin Immunol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  946-53     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intranasal
Budesonide
Double-Blind Method
Glucocorticoids / therapeutic use
Humans
Nasal Polyps / drug therapy*,  physiopathology
Patient Compliance
Placebos
Pregnenediones / adverse effects,  therapeutic use*
Pulmonary Ventilation
Chemical
Reg. No./Substance:
0/Glucocorticoids; 0/Placebos; 0/Pregnenediones; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and purification of an important cross-reactive allergen from American (Periplaneta a...
Next Document:  Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital ana...